Press Releases

February 17, 2016
Protagonist Therapeutics Names Thomas P. O'Neil Chief Financial Officer Read More
January 8, 2016
Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 Read More
October 20, 2015
Two Poster Presentations on Oral Peptides by Protagonist Therapeutics Accepted for the Upcoming 2015 Advances in IBD – Crohn’s & Colitis Foundation’s Clinical & Research Conference Read More
September 23, 2015
Protagonist Therapeutics Receives SBIR Funding for Oral IL-23 Receptor Antagonists for Treatment of Inflammatory Bowel Diseases Read More
September 10, 2015
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer Read More
July 16, 2015
Protagonist Therapeutics Raises $40 Million Series C Financing to Advance Oral Peptide Drugs into Clinical Development Read More
December 18, 2014
Protagonist Therapeutics Names William A. Hodder as Senior Vice President, Corporate Development Read More
December 4, 2014
Protagonist Therapeutics Closes 2nd Tranche of $18 Million Series B for Advancing Development Candidate to Clinical Trials in 2015 Read More
November 5, 2014
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors Read More
September 19, 2013
Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard Read More
June 4, 2013
Protagonist Therapeutics Raises $14 Million in Series B Venture Financing Read More
May 30, 2013
Protagonist Therapeutics Names David Liu Chief Scientific Officer Read More
December 6, 2012
Protagonist and Ironwood Expand Peptide Drug Discovery Collaboration Read More
June 18, 2012
Zealand Pharma and Protagonist Therapeutics Team Up for Peptide Drug Discovery and Development Read More
January 18, 2011
Ironwood and Protagonist Establish Collaboration for Peptide Drug Discovery and Development Read More